Dasatinib Induces a Response in Malignant Thymoma
Dasatinib is a novel, oral, multitargeted kinase inhibitor of Bcr-Abl and Src family kinases, as well as ephrin receptor kinases, platelet-derived growth factor receptor, and c-Kit.
Read More →